News
Ambit in the Media
BioWorld Today discusses Ambit’s Series D Financing – November 2007 In a frontpage article focused on Ambit’s $43.9 million Series D Financing, BioWorld Today discusses the company’s new and existing investors as well as its kinase inhibitor programs and new additions to its board of directors. Access the full article [64KB] bizSanDiego features the history of Ambit Biosciences and gets up close and personal with CEO, Scott Salka – January 2007 In its January cover story, bizSanDiego examines the history of…
Announcing the 2006 Fierce 15
FierceBiotech, April 2006 If you look over the biotech companies on this year’s list, you’ll see a few common attributes: There’s a big emphasis on efficient use of capital; more of these up-and-coming biotechs are striking licensing deals with major pharma partners at an earlier stage than ever; and the valuations they appear to be getting are strong. If you’ve got good science, there’s never been a better time to be a biotechnology company. Over the rest of the year,…